SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R on behalf of the Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 126778.
  • 2
    Medicines and Healthcare Products Regulatory Agency. Reclassification summary for simvastatin POM to P. 2004. Available at http://medicines.mhra_gov.uk (last accessed 10 March 2009).
  • 3
    Johnson & Johnson MSD Consumer Pharmaceuticals. Zocor Heart-Pro Pharmacist Training Guide. 2004.
  • 4
    Royal Pharmaceutical Society of Great Britain. Practice guidance: OTC simvastatin 10 mg. Pharm J 2004; 273: 16970.
  • 5
    Medicines and Healthcare Products Regulatory Agency. Responses to ARM18: request to reclassify simvastatin 10 mg. 2003. Available at http://medicines.mhra_gov.uk (last accessed 10 March 2009).
  • 6
    Bayliss E, Rutter P. General practitioners' views on recent and proposed switches from POM to P. Pharm J 2004; 273: 81921.
  • 7
    Anonymous. Editorial. Over-the-counter simvastatin given the go-ahead. Pharm J 2004; 272: 595.
  • 8
    Gibson L. Moves to sell statins over the counter raises concerns. Br Med J 2004; 328: 1221.
  • 9
    Anonymous. Editorial. OTC Statins: a bad decision for public health. Lancet 2004; 363: 9422.
  • 10
    Hansford D, Cunningham S, John D, McCaig D, Stewart D. Community pharmacists' views, attitudes and early experiences of over-the-counter simvastatin. Pharm World Sci 2007; 29: 3805.